8-K: Pulmonx Reports Q2 2026 Results, Revenue Down 5%

Pulmonx Corporation announced its second quarter 2026 financial results, reporting a 5% decrease in worldwide revenue to $22.8 million, but a significant reduction in net loss and adjusted EBITDA loss due to cost realignment.

Summary

• Pulmonx Corporation reported second quarter 2026 worldwide revenue of $22.8 million, a 5% decrease compared to the same period last year.
• U.S. revenue decreased by 4% to $14.2 million, and international revenue decreased by 6% to $8.6 million.
• Excluding China, international revenue saw a year-over-year increase of 12% (9% on a constant currency basis), attributed to a temporary halt in sales to China due to registration certificate renewal.
• Gross margin improved to a record 78% in the second quarter of 2026, up from 72% in the prior year.
• Operating expenses were reduced by 16% to $26.8 million.
• Net loss for the quarter was $10.1 million ($0.24 per share), a decrease from $15.2 million ($0.38 per share) in the second quarter of 2025.
• Adjusted EBITDA loss also decreased by 39% to $5.1 million from $8.4 million in the prior year.
• The company maintained its full-year 2026 revenue outlook of $90 million to $92 million and now expects full-year gross margin of approximately 76%.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious sentiment score due to the reported revenue decline, despite positive operational improvements and cost reductions. The company's ability to return to revenue growth is a key factor to monitor.

Positives

• Achieved record gross margin of 78% in Q2 2026, an improvement from 72% in Q2 2025.
• Reduced net loss by 34% to $10.1 million in Q2 2026 compared to $15.2 million in Q2 2025.
• Reduced adjusted EBITDA loss by 39% to $5.1 million in Q2 2026 compared to $8.4 million in Q2 2025.
• Operating expenses decreased by 16% to $26.8 million in Q2 2026.
• International revenue excluding China grew 12% year-over-year.
• Full-year 2026 revenue guidance remains at $90 million to $92 million.
• Full-year 2026 gross margin is now expected to be approximately 76%.

Negatives

• Worldwide revenue decreased by 5% to $22.8 million in Q2 2026 compared to $23.9 million in Q2 2025.
• U.S. revenue decreased by 4% to $14.2 million in Q2 2026.
• International revenue decreased by 6% to $8.6 million in Q2 2026.
• Cash and cash equivalents decreased to $55.8 million as of June 30, 2026, from $69.8 million as of December 31, 2025.
• The company expects cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026.

Risks

• The decrease in international revenue was attributable to a lack of sales into China as the company awaited the renewal of its registration certificate.
• Forward-looking statements are subject to numerous risks and uncertainties, including those detailed in the Risk Factors section of Pulmonx's public filings with the SEC.

Future Outlook

The company expects full-year 2026 revenue to be in the range of $90 million to $92 million. Full-year 2026 gross margin is now expected to be approximately 76%. Total operating expenses for the full year 2026 are expected to be between $109 million and $111 million. Cash, cash equivalents, and marketable securities are expected to decrease by approximately $23 million for the full year 2026.

Management Comments

• "We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to deliver the significant operating leverage we expected," said Glen French, President and Chief Executive Officer of Pulmonx.
• "With a fully staffed US sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to return to year-over-year revenue growth and drive meaningful operating leverage while advancing our longer-term strategic priorities."

Industry Context

StockSavvy.ai notes that Pulmonx's Q2 2026 results reflect ongoing challenges in revenue growth within the specialized medical device sector for respiratory diseases, particularly impacted by temporary regulatory hurdles in key international markets like China. However, the significant improvements in gross margin and reduction in operating expenses and net loss demonstrate successful cost management and operational efficiency efforts, which are critical for companies in this capital-intensive industry aiming for profitability.

Comparison to Industry Standards

• The reported gross margin of 78% is exceptionally strong for a medical device company, often exceeding industry averages which can range from 50-70% depending on product complexity and market penetration.
• The reduction in net loss and adjusted EBITDA loss, while revenue declined, indicates a positive trend in operational leverage. Many companies in the medical technology space focus on achieving profitability through scale and cost control after initial product development and market entry.
• The revenue decline, particularly in international markets due to specific regulatory issues (China), highlights the geopolitical and regulatory risks common in global medical device markets. Competitors often face similar challenges with market access and product approvals in different regions.

Stakeholder Impact

• Shareholders: The revenue decline may be a concern, but the improved margins and reduced losses could signal a path to future profitability. The maintained revenue guidance offers some stability.
• Employees: Cost realignment efforts may have implications for staffing, though the focus on a 'more focused global commercial team' suggests strategic adjustments.
• Customers: Continued focus on minimally invasive treatments for COPD and emphysema suggests ongoing commitment to patient care.
• Suppliers: Reduced operating expenses could indirectly impact supplier relationships through volume adjustments.

Next Steps

• Continue executing commercial strategy.
• Advance clinical initiatives.
• Drive year-over-year revenue growth.
• Drive meaningful operating leverage.
• Advance longer-term strategic priorities.

Key Dates

Recommendation

The recommendation is 'hold' because while the company has demonstrated significant improvements in cost management, gross margins, and reduced losses, the core issue of declining revenue needs to be addressed. The company's confidence in returning to revenue growth and the maintained full-year revenue guidance are positive, but the current trend warrants a cautious approach until sustained growth is evident.

Keywords

minimally invasive treatments, lung disease, COPD, emphysema, Zephyr Endobronchial Valve, financial results, revenue, gross margin